Celltrion, Inc. today showcased real-world evidence supporting the use of subcutaneous (SC) infliximab, confirming the efficacy and safety of switching to SC infliximab 120mg every two weeks in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback